Amit Goyal, MD

DocwireNews

Promising long-term outcomes from the ongoing Open-Label Extension (OLE) of the ATTRibute-CM trial highlight the efficacy of acoramidis, an investigational therapy for transthyretin cardiac amyloidosis (ATTR-CM). Presented at the 2024 AHA Scientific Sessions, the study underscores acoramidis’ significant reductions in all-cause mortality (ACM) and cardiovascular hospitalizations (CVH), reinforcing its potential as a transformative therapy for this progressive disease.
ATTR-CM results from transthyretin protein misfolding, leading to cardiac dysfunction and heart failure. Acoramidis is a next-generation TTR stabilizer achieving ≥90% stabilization in clinical trials. The Phase 3 ATTRibute-CM trial previously demonstrated significant reductions in ACM, CVH, and improvements in biomarkers and functional outcomes over 30 months. This ongoing OLE investigates acoramidis’ long-term effects over 36 and 42 months.
Participants completing the ATTRibute-CM trial were enrolled in the OLE and received 800 mg acoramidis hydrochloride twice daily. The study employed Cox proportional hazards models to evaluate time-to-first event analyses for ACM, the composite of ACM or first CVH, and first CVH alone. An Andersen-Gill analysis assessed recurrent ACM and CVH events.
The OLE findings demonstrate continued and significant benefits:
<ul>
<li>Compared to placebo, acoramidis reduced ACM by 35.7% and 33.7% at 36 and 42 months, respectively (p&lt;0.01 for both).</li>
<li>Composite ACM and first CVH were reduced by 34.3% at 36 months and 33.9% at 42 months (both p&lt;0.0001).</li>
<li>First CVH alone was reduced by 40.5% at 36 months and 41.0% at 42 months (both p&lt;0.0001).</li>
<li>Recurrent events (ACM and CVH) showed a 34% and 39% reduction at 36 and 42 months, respectively (both p&lt;0.0001).</li>
</ul>
The safety profile of acoramidis remains consistent with the parent trial.
 Takeaways
These results affirm acoramidis’ durable benefits in reducing mortality and hospitalizations for ATTR-CM patients, with trends suggesting improved survival in patients who transitioned from placebo to acoramidis. The findings highlight the importance of early and sustained treatment for achieving optimal outcomes in ATTR-CM management. With its strong safety profile and significant clinical efficacy, acoramidis represents a major advance in treating transthyretin cardiac amyloidosis.
Reference
Judge D, Gilmore J, Alexander K, et al. Acoramidis Reduces All-Cause Mortality (ACM) and Cardiovascular-Related Hospitalization (CVH): Initial Outcomes From the ATTRibute-CM Open-Label Extension (OLE) Study. Presentation #4172052. Presented at the American Heart Association Scientific Sessions 2024; November 16-18, Chicago, Illinois.

Jordana Jampel

Eight Contributing Factors to Increasing Heart Disease Incidence in Some Global Regions

Stroke

New Findings on Myelin Mechanism Involved in Genetically Based Autism

Neurodivergent

AGA Guideline Update on Pharmacologic Ulcerative Colitis Treatment

Gastroenterology

Latest News

Acoramidis Demonstrates Long-Term Benefits in ATTR-CM: Results from the ATTRibute-CM Open-Label Extension

AHA 2024: CardioNerds

Promising long-term outcomes from the ongoing OLE of the ATTRibute-CM trial highlight the efficacy of acoramidis.

Acoramidis Demonstrates Long-Term Benefits in ATTR-CM

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe